Purpose: A thorough understanding of the natural history and consensus regarding the optimal management of pathological lymph node positive (pN1) prostate cancer are lacking. Our objective was to describe patterns of care and outcomes of a contemporary cohort of men with pN1 prostate cancer. Materials and Methods: We used the National Cancer Database to identify 7,791 men who were found to have lymph node metastases at radical prostatectomy. Multinomial logistic regression and Cox proportional hazards regression were used to identify patient, tumor and facility characteristics associated with the choice of management strategy after radical prostatectomy and overall survival, respectively. Results: Initial post-prostatectomy management was observation in 63% of the men, androgen deprivation therapy alone in 20%, radiation therapy alone in 5%, and androgen deprivation therapy and radiation therapy in 13%. Younger age, lower comorbidity burden, higher grade and stage, and positive surgical margins were associated with a higher likelihood of receiving combination therapy. Grade group 4e5 disease, pT3b-T4 disease, positive surgical margins and a higher number of positive lymph nodes were independent predictors of worse overall survival. The adjusted 10-year overall survival probability decreased from 84% to 32% with the presence of an increasing number of adverse prognostic factors. Treatment with combined androgen deprivation therapy and radiation therapy was associated with better overall survival (multivariable HR 0.69, 95% CI 0.52e0.92, p ¼ 0.010 for combination therapy vs observation). Conclusions: Patient and tumor characteristics are associated with the choice of management strategy after radical prostatectomy and survival in men with pN1 prostate cancer. Multimodal therapy may be of benefit in this patient population.
LYMPH node metastases in men with adenocarcinoma of the prostate who undergo RP have traditionally been thought to be a manifestation of widely disseminated disease and consequently portend a poor prognosis. This paradigm was the basis of an ECOG randomized trial comparing immediate vs delayed ADT, which showed higher OS among men who received immediate as opposed to delayed ADT. 1 However, recent observational studies have shown that even in the absence of any treatment 10-year cancer specific survival in men with pN1 disease can be as high as 70%. 2 This suggests that immediate and lifelong ADT represents overtreatment in most such men.
Furthermore, there is a lack of data on the role of RT after RP in men with pN1 disease as prior randomized trials of adjuvant RT excluded men with LN metastases. 3e5 The uncertainty regarding the optimal management of these cases is reflected in NCCNÒ (National Comprehensive Cancer NetworkÒ) clinical practice guidelines, which list observation, adjuvant ADT, and adjuvant ADT and RT as acceptable management options for pN1 disease. 6 Although these issues make it likely that immediate treatment with ADT and/or RT has not been widely adopted in contemporary clinical practice, studies examining patterns of care after RP in this patient population are lacking. Additionally, it is unknown whether the favorable outcomes reported from high volume academic centers apply to all men with pN1 disease. To address these knowledge gaps we sought to describe treatment and outcomes of a large, diverse and contemporary cohort of men with pN1 prostate cancer.
MATERIALS AND METHODS
We used the NCDB to identify 283,802 men without a history of malignancy who were diagnosed with nonmetastatic adenocarcinoma of the prostate between 2004 and 2014 and treated with RP. Of these patients 9,673 (3.4%) were found to have LN metastases. We excluded from analysis 227 men who received chemotherapy, 1,117 treated with ADT or RT prior to RP and 537 with missing data on whether ADT or RT was administered or the timing of these treatments. We also excluded 1 patient who was an extreme outlier with respect to the number of LNs removed (88). This left 7,791 men for inclusion in the analysis of the choice of post-RP management strategy.
Only men diagnosed between 2004 and 2010 were included in survival analyses to allow for sufficient followup. Of the 3,988 men diagnosed during this period 104 were excluded because of missing data on followup time and an additional 204 were excluded because they died or were lost to followup within 1 year of RP. The remaining 3,680 men were included in survival analyses.
The primary objectives of our study were to identify patient, tumor and facility characteristics associated with the choice of post-RP management strategy and survival. Management strategies were categorized as 1) observation and treatment with 2) ADT alone, 3) RT alone or 4) ADT plus RT within 12 months of RP.
Multinomial regression was used to model the relationships between patient, tumor and facility characteristics, and post-RP management strategies. Survival analyses were performed using Cox proportional hazards regression. To limit time to treatment bias we performed a landmark analysis 7 in which followup was defined as starting 12 months after RP. All models included age, CCI, race, insurance status, income, urbanicity, facility location, facility designation, annual facility pN1 prostate cancer case volume, year of diagnosis, grade group, pathological T stage, margin status, and number of positive and negative LNs removed.
Robust SEs were used to account for clustering of outcomes of patients treated at the same facility. Multiple imputation by chained equations was done to account for missing covariate data, the frequency of which varied from a high of 7% for PSA to less than 3% for all other covariates. All statistical tests were 2-sided with p <0.05 considered significant. Statistical analyses were performed with StataÒ, version 14.
RESULTS
Of the men 51% had grade group 4-5 disease and 81% had pT3-T4 disease (table 1). The incidence of positive surgical margins was 47%. The median LN yield was 9 (IQR 5e14) and the median number of positive LNs was 1 (IQR 1e2).
Of the men 63% received no ADT or RT within 12 months of RP while 20% were treated with ADT alone, 5% were treated with RT alone and 13% received ADT plus RT. Administration of combination therapy increased with time, with 15% of men diagnosed in 2014 receiving ADT and RT compared to 8% of those diagnosed in 2004 ( fig. 1 ). This modest rise was statistically significant even after accounting for all other covariates on multivariable analysis (p trend <0.001).
Predictors of post-RP management strategy are shown in table 2. Treatment with ADT alone was more common at academic facilities. Older patients and men with more comorbidities were less likely to receive combination therapy or RT alone compared to observation. Likewise, black patients were less likely to receive combination therapy than observation. 
Percentages may not total 100% because of rounding. * Collapsed to comply with NCDB stipulation against reporting counts less than 10.
Men with higher grade tumors were more likely to be treated with ADT alone than observation, RT alone or combination therapy. Men with higher stage tumors and those with positive surgical margins were more likely to receive any treatment than undergo observation and they were also more likely to be treated with combination therapy than ADT alone. Men with a higher positive LN count were more likely to receive ADT alone compared to all other management strategies and more likely to receive combination therapy compared to RT alone. Higher preoperative PSA was also associated with a higher likelihood of treatment with ADT alone compared to observation.
Of the 3,680 patients included in survival analyses 641 died during followup. Median followup from the date of RP in survivors was 5.9 years (IQR 4.7e7.7). The probability of being alive 5 and 10 years after RP, conditional on surviving at least 1 year after surgery, was 89% (95% CI 87e90) and 66% (95% CI 63e69), respectively. Table 3 lists associations between patient, tumor and facility characteristics, and survival. Grade group 4-5 disease, pathological stage T3b-T4 disease and positive surgical margins were independent predictors of worse OS. Survival was also associated with the nodal disease burden with the optimal cutoff point determined to be 3 LNs. The adjusted 10-year OS probability in patients with 0, 1, 2, 3 and 4 of the listed adverse pathological features was 84%, 75%, 65%, 51% and 32%, respectively (table 4) .
On multivariable analysis the combination of ADT and RT was associated with significantly lower all cause mortality compared to observation (multivariate HR 0.69, 95% CI 0.52e0.92, p ¼ 0.010) and ADT alone (HR 0.65, 95% CI 0.48e0.89, p ¼ 0.008, fig. 2 ).
Treatment with ADT or RT alone was not associated with better or worse OS compared to observation. The adjusted 10-year OS probability conditional on surviving at least 1 year after RP in patients treated with observation, ADT alone, RT alone and ADT and RT was 69%, 67%, 75% and 77%, respectively.
DISCUSSION
Using a large and nationally representative cohort we found that contemporary treatment of men with pN1 prostate cancer varies according to clinical and institutional characteristics. Although the use of combined ADT and RT appears to be increasing at a modest rate, multimodal therapy continues to be administered much less frequently than observation or ADT alone despite accumulating evidence that it is associated with better outcomes.
The prevalence of LN metastases among men who undergo RP has historically been reported to be low. 8 However, it strongly correlates with the thoroughness of LN dissection and the pathological characteristics of the primary tumor. 9, 10 Given the expected reverse stage migration precipitated by the USPSTF (U.S. Preventive Services Task Force) recommendations against prostate cancer screening, the shift toward performing RP in more patients with high risk disease and the increasing use of extended LN dissection, the number of men with pN1 prostate cancer is expected to increase. These temporal trends along with the unequivocally detrimental impact of LN metastases on survival 11 make understanding the natural history of and defining the optimal management strategy for pN1 prostate cancer issues of increasing importance.
To our knowledge ours is the largest study examining patterns of care in men with pN1 prostate cancer. A prior study that used the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database to describe treatment in 731 men with pN1 prostate cancer diagnosed between 1991 and 1999 reported that 61% were treated with observation and only 2% received ADT plus RT. 12 In a subsequent SEER-Medicare analysis of 577 men diagnosed between 1995 and 2007 the reported proportion of those who received combination therapy was 8%, 13 further supporting the notion that the use of combination therapy has increased modestly with time. Neither of these studies assessed factors influencing the choice of post-RP management strategy.
Importantly our findings suggest that clinicians consider the pathological characteristics of the primary tumor as well as the burden of LN metastases when deciding on management. Specifically we found that patients with higher grade tumors and a greater number of positive LNs were more likely to be treated with ADT alone than observation, RT alone or combination therapy. This is done despite the general lack of evidence that men with higher grade disease and a higher metastatic LN burden are less likely to benefit from additional local therapy. The finding that black men with pN1 disease are less likely than white men to receive combination therapy is consistent with prior studies showing less frequent administration of definitive local therapies among black men with clinically localized prostate cancer. 14, 15 This suggests that improving access to multimodal therapy may help address racial disparities in outcomes among men with this disease.
The finding of LN metastases at RP has traditionally been thought to portend synchronous extranodal metastatic disease and, therefore, a uniformly poor prognosis, a paradigm whose validity is being increasingly challenged. 16 Many men with pN1 disease do not experience disease recurrence during long-term followup as shown in a study from our institution that revealed a 10-year metastasis-free survival probability of 65% in a cohort of men not given adjuvant ADT or RT. 2 The current series confirms that most men with pN1 prostate cancer have favorable outcomes, as 89% and 66% in our cohort were alive 5 and 10 years after RP, respectively. However, it also draws attention to substantial variation in the prognosis of individual patients. As also revealed in several prior single institution series we found that grade group 4e5 disease, pT3b-T4 disease, positive surgical margins and an increasing number of positive LNs were independent predictors of worse OS. 17, 18 This highlights the fact that the natural history of pN1 prostate cancer is driven as much by the characteristics of the primary tumor as by the burden of LN metastases.
We also found that while combination therapy was associated with a significant reduction in all cause mortality compared to observation alone, monotherapy with ADT or RT was not. These findings contrast to those of ECOG EST-3886, a randomized trial that showed that immediate ADT was superior to observation with delayed treatment with respect to OS in pN1 cases. 1 The discrepant results pertaining to the benefit of ADT monotherapy may be explained by differences between the 2 study populations. Specifically patients enrolled in the ECOG trial had a higher incidence of positive surgical margins and seminal vesicle invasion, and a higher average number of positive LNs. These differences likely explain the significantly higher all cause mortality in the observation arm of the ECOG trial, which approached 50% at 10 years, compared to our cohort, in which the adjusted 10-year all cause mortality was only 31%. Additionally, treatment of men in the observation arm of the ECOG trial was deferred until development of clinical recurrence, which does not reflect contemporary practice.
In contrast, our finding of improved OS with multimodal therapy is in line with findings of recent observational studies. In the largest such study published to date, which included a total of 1,107 patients at 2 tertiary care centers, cancer specific and all cause mortality were significantly lower in men who received ADT plus RT compared to those who received ADT alone. 19 Subgroup analyses suggested that the beneficial effect of combination therapy was limited to patients with 1 or 2 positive LNs and pT3b-pT4 disease or positive surgical margins and those with 3 or 4 positive LNs irrespective of other tumor characteristics.
The limitations of our analysis with respect to determining whether the association between post-RP management and survival is causal must be acknowledged. Most importantly the NCDB does not contain information on post-RP PSA levels. This is an important limitation, given that undetectable PSA after RP was shown to be an independent predictor of survival in patients with pN1 disease. 20 It is possible that men in whom PSA does not become undetectable after surgery or rises rapidly after becoming undetectable are less likely to receive combination therapy instead of ADT alone or observation as they are regarded as having systemic disease and, therefore, are less likely to benefit from local therapy.
Furthermore, because of a lack of data on recurrence, we could not address the question of whether combination therapy given in an adjuvant setting is superior to early salvage therapy at the time of PSA recurrence.
Lastly, the benefit of ADT and RT with respect to potentially prolonging survival must be balanced against the significant toxicities associated with these treatments, which are not captured in the NCDB.
Strengths of our study include a large sample size and a followup of sufficient length to capture most cancer related deaths in this high risk population. The main limitation is that the observational nature of the study means that the results are susceptible to bias due to unmeasured or residual confounding. The study was also limited by the absence of information on surgical approach and the administration of novel hormonal therapies and chemotherapy in men in whom castrate resistant disease eventually developed.
CONCLUSIONS
We describe significant heterogeneity in post-RP treatment and outcomes of men with pN1 prostate cancer. Our data suggest that combined ADT and RT may be associated with a survival benefit in this setting. This finding is in line with the findings of prior observational studies and suggests that a randomized trial of multimodal therapy is warranted in this population.
